Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
about
Guanylate cyclase stimulators for pulmonary hypertensionInhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migrationLong-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.Cold hands--strained heart? Advances in the management of Raynaud's phenomenon and pulmonary hypertensionGuanylate cyclase stimulators for pulmonary hypertensionGiant, dissecting, high-pressure pulmonary artery aneurysm: case report of a 1-year natural courseThe soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in ratsSildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells.Thrombosis, platelets, microparticles and PAH: more than a clot.Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice.NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity.Developmental expression of vasoactive and growth factors in human lung. Role in pulmonary vascular resistance adaptation at birth.Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variabilitySildenafil citrate for the treatment of pulmonary arterial hypertension.Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.Quantitative Dual-Energy Computed Tomography Supports a Vascular Etiology of Smoking-induced Inflammatory Lung Disease.Signal transduction in the development of pulmonary arterial hypertensionAdvances in therapies for pediatric pulmonary arterial hypertension.Riociguat for the treatment of pulmonary hypertension.Tadalafil for the treatment of pulmonary arterial hypertension.Pulmonary Hypertension and Cardiopulmonary Exercise in Heart Failure.Advances in treatment of pulmonary arterial hypertension: patent review.The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies.Sildenafil for pulmonary arterial hypertension.Liposomal Aerosols of Nitric Oxide (NO) Donor as a Long-Acting Substitute for the Ultra-Short-Acting Inhaled NO in the Treatment of PAH.Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching.High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension.Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension.Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice.Pulmonary Arterial Hypertension in Women.Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator
P2860
Q24195067-3EC7CDAD-7B3F-4165-92F7-4266962A9B76Q24812224-2A5A0E55-E0A8-479B-9C1F-83399723F0FBQ24813821-EFB45E15-6E3C-4A5C-A64A-AFF83F8E6AE3Q24816970-9B76FF3E-E31B-4B66-954A-C7DA52F35B08Q26470534-81762C76-1842-4570-9B8A-F8364ADDFDF3Q30502967-F503A275-3895-4D3D-AD2F-323758590F92Q34389618-C2B6417F-6126-4334-BBC8-83BF3D8B3483Q35049122-F1281E3A-D62B-42F7-AE5A-001F020E4BA3Q35276116-909E730E-9BE2-450F-9DF4-0239EA574AFAQ35572413-C38528A5-9175-407E-B5C5-9C1A23078461Q35605567-647A76C6-9BC6-4E2B-9684-4A6EB9CE9235Q36092149-8BAB696D-342A-4589-8645-82F126ED5B78Q36382353-054688B9-9A50-4BF6-A5AC-47E4926691A9Q36429756-67C8C02C-2D80-4FA6-BD04-DC60D89C6FC0Q36577383-8738D17B-07EA-49FE-A575-DF7E6DA4503AQ36778614-715BDDD2-C946-439A-A793-FA253179D549Q37133785-4E2077B2-1EEA-4EFE-AFAF-E432DF17D241Q37755020-C514BA88-9DD2-45BF-A34A-EE8037CFA6E2Q37851516-56825717-0AA5-4815-AC52-FD6C5E5CA70CQ37894086-9F7EEF82-9B13-4B05-B321-B705B80F22A9Q38590116-02923FCC-CD46-4588-862F-15BE3BD43A3DQ39206788-5E363D72-DBEF-4A58-90FB-7BF14DEC9F90Q39353707-EA48A603-0867-43D1-AA42-6C7DB5D95158Q40347890-6CD657DD-275F-4BCC-BABB-46D6F6193432Q42132055-80C26210-1202-4590-8BFD-3404C695F099Q42822789-4603B9DE-D3BC-45DB-81B8-C45CDF40F8E1Q46936674-CC147015-480A-4AD3-9EF8-B8681CF66FC1Q47648931-B44AC0F8-3F92-445F-8796-F7983DA41254Q50793400-26D44EF0-B9FA-45E3-8525-D36FE60ACB32Q50853728-D094C97B-9F46-4E9E-8B4F-B6A197AACF61Q52877853-E4B4A124-323A-4F80-B4B7-1D33268A1094Q55408049-A6BB3AD1-58B1-4F44-8B97-17407FDD9C86Q57495849-BA1A33A7-ABF0-4528-BBB2-51A4B0D17D54
P2860
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
@ast
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
@en
type
label
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
@ast
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
@en
prefLabel
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
@ast
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
@en
P2093
P1476
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension
@en
P2093
Anne M Keogh
Friedrich Grimminger
Joanna Pepke-Zaba
Meinhard Kneussl
Miguel A Gomez-Sanchez
Richard Channick
P304
P356
10.1016/J.JACC.2004.02.031
P407
P433
12 Suppl S
P577
2004-06-01T00:00:00Z